NeoGenomics (NEO) Tops Q2 EPS by 1c, Beats on Revenues; Reiterates Guidance

NeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $66.1 million versus the consensus estimate of $62.97 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Creatd files Form S-1 and reports Q1 2026 financial results
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform